ITS Interim

 
Fund Quotes for ITS Interim top ^
  • Category: Short Government
  • Morningstar Rating: 3 Stars
Sign-up for sfitx investment picks

 
News Articles for ITS Interim top ^
LA JOLLA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Auspex Pharmaceuticals, Inc. (Nasdaq:ASPX) , a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, today announced results from a pre-specified interim subgroup analysis of the ongoing open-label ARC-HD Switch study in which the clinical experience of switching subjects' treatment from tetrabenazine to SD-809 was evaluated.
Sign-up for Auspex Pharmaceuticals Announces Data From Interim Analysis of ARC-HD Switch Trial Demonstrating Clinical Activity of SD-809 investment picks
2014/8/14
Highlights For the second quarter of 2014, KNOT Offshore Partners LP (“KNOT Offshore Partners” or the “Partnership”): Net income in the second quarter of 2014 was affected by $1.6 million in unrealized mark to market losses on derivatives and approximately $2.2 million in transaction costs on refinancing, acquisitions and preparation for the Partnership’s June 2014 common unit offering.
Sign-up for Knot Offshore Partners LP Earnings Release - Interim Results for the Period Ended June 30, 2014 investment picks
2014/6/24
Patients treated with Squalamine eye drops plus Lucentis ® PRN demonstrated a 65 percent additional relative benefit in visual acuity versus placebo eye drops plus Lucentis PRN Percentage of Squalamine plus Lucentis PRN-treated patients gaining three, four and five lines in visual acuity was more than double the placebo plus Lucentis PRN arm Conference call and webcast scheduled for 8:30 a.m. EDT NEW YORK, June 24, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) , an ophthalmology research and development company, today announced positive top-line interim results for its double-masked, placebo-controlled Phase II clinical trial of Squalamine eye drops in patients with wet age-related macular degeneration (wet AMD). The data demonstrated a positive benefit in visual function across multiple clinically relevant endpoints, including a mean change in visual acuity at the end of study visit for the interim analysis group of +10.4 letters with
Sign-up for Ohr Pharmaceutical Announces Positive Interim Top-Line Clinical Results From Phase II Study of Squalamine Eye Drops in Patients With Wet AMD investment picks
2014/8/13
Phase III Trial Is Alive And Well; "Hint Of Failure" A Complete Fabrication; No Interim Analysis of Efficacy Done; 55 Patients' Positive Data Independently Collected.
Sign-up for NW BIO CORRECTS ONGOING FALSE CLAIMS BY FEUERSTEIN ABOUT PHASE III TRIAL OF DCVAX®-L, AND INTERIM ANALYSIS investment picks
Analgesia in a subset of patients (50%), suggests therapeutic potential for Dex-IN in Post Op Day 1 MALVERN, Pa., Sept.
Sign-up for Recro Pharma Provides Clinical Strategy Update Following Interim Analysis for Phase IIb Clinical Trial of Dex-IN investment picks
NEWARK, Calif., June 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SC ® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12 th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.
Sign-up for StemCells, Inc. Interim Results Show Improvement in Visual Function and Slowing of Disease Progression in Phase I/II Dry AMD Trial investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1140806&ProfileId=051205&sourceType=1 LONDON, UNITED KINGDOM --
Sign-up for Anglo Pacific Group PLC: Interim results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1137759&ProfileId=051205&sourceType=1 PERTH, AUSTRALIA --
Sign-up for Centamin PLC Announces Q2 Results 2014 and Maiden Interim Dividend investment picks
Taxus Cardium Pharmaceuticals Group Inc. (OTCQB: CRXM) will report today at the Biotechnology Industry Organization’s 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx ® Ad5FGF-4, Cardium Therapeutics’ angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.
Sign-up for Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention investment picks
2014/6/24
Pioneering Angiogenic Gene Therapy for the Potential Treatment of Millions of Patients with Heart Disease Worldwide SAN DIEGO , June 24, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx ® Ad5FGF-4, Cardium Therapeutics' angiogenic gene therapy product candidate for patients with myocardial ischemia due to coronary artery disease.
Sign-up for Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International Convention investment picks
OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today announced 6 month results of a Phase 2 dose-finding study evaluating the safety and efficacy of its novel long-acting human growth hormone product (Lagova) to treat pediatric growth hormone deficiency disorder (GHD). All three Lagova once-weekly doses demonstrate strong catch-up growth during the six months treatment.
Sign-up for OPKO Announces Positive Interim Six-Month Lagova™ (hGH-CTP) Phase 2 Data in Pediatric Growth Hormone Deficiency Disorder investment picks
MGE Energy, Inc. (Nasdaq: MGEE) today published its investor newsletter "Interim Report" with the following topics: - MGE Energy increases its dividend for 39 consecutive years - Second-quarter earnings reported - MGE a leader in green energy - New environmental controls now online at Columbia Energy Center The newsletter is available on MGE Energy's website at: http://www.mgeenergy.com/interimreport Interim Report is published quarterly to provide investors with information about MGE Energy and its primary subsidiary, Madison Gas and Electric.
Sign-up for MGE Energy Issues September 2014 'Interim Report' investment picks
2014/8/26
Jaguar Mining Announces Filing of Interim Financial Statements Canada NewsWire TSX-V:JAG TORONTO , Aug.
Sign-up for Jaguar Mining Announces Filing of Interim Financial Statements investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1138376&ProfileId=051205&sourceType=1 LONDON, UNITED KINGDOM --
Sign-up for Anglo Pacific Group PLC: Notice of Results: Interim Results for 2014 investment picks
HOUSTON and LONDON , Aug.
Sign-up for LyondellBasell Board Authorizes Interim Dividend investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1137095&ProfileId=051205&sourceType=1 LONDON, UNITED KINGDOM --
Sign-up for Serica Energy plc Announces Interim Results investment picks
DigitalGlobe (NYSE: DGI), a leading provider of commercial high-resolution earth observation and advanced geospatial solutions, today announced that Fred Graffam will become Interim Chief Financial Officer for the company, effective Sept.
Sign-up for DigitalGlobe Names Interim Chief Financial Officer investment picks
Novatel Wireless, Inc. (NASDAQ: NVTL), a leading provider of machine to machine (M2M) wireless solutions, announced that the Board of Directors has appointed Tom Allen as Interim Chief Financial Officer.
Sign-up for Novatel Wireless Appoints Interim Chief Financial Officer investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
ITS Interim
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Istar Financial  |  Next: Ivanhoe Energy